Latest Vascular endothelial growth factor Stories
TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
DME is the third approved indication for EYLEA in the U.S. TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
TARRYTOWN, N.Y., July 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
A form of Vitamin E has been found to block a protein that mesothelioma cells need to form new blood vessels. Raleigh, NC (PRWEB) July 10, 2014 Scientists
MARLBOROUGH, Mass., July 7, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies
ROCKVILLE, Md., July 7, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc.
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival.
TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
Common stock to begin trading under "CASI" on June 16, 2014 ROCKVILLE, Md., June 13, 2014 /PRNewswire/ -- EntreMed, Inc.
INDIANAPOLIS, June 11, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Phase III REACH trial of CYRAMZA(TM) (ramucirumab) in patients with hepatocellular carcinoma,
- Withering but not falling off, as a blossom that persists on a twig after flowering.